Trials / Completed
CompletedNCT03347110
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Bimekizumab at a prespecified dose. |
Timeline
- Start date
- 2017-11-22
- Primary completion
- 2020-10-29
- Completion
- 2020-10-29
- First posted
- 2017-11-20
- Last updated
- 2023-12-01
- Results posted
- 2023-12-01
Locations
37 sites across 6 countries: United States, Czechia, Germany, Hungary, Poland, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03347110. Inclusion in this directory is not an endorsement.